Literature DB >> 12069963

Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori.

Gary Sisson1, Avery Goodwin, Ausra Raudonikiene, Nicky J Hughes, Asish K Mukhopadhyay, Douglas E Berg, Paul S Hoffman.   

Abstract

Nitazoxanide (NTZ) is a redox-active nitrothiazolyl-salicylamide prodrug that kills Helicobacter pylori and also many anaerobic bacterial, protozoan, and helminthic species. Here we describe development and use of a spectrophotometric assay, based on nitroreduction of NTZ at 412 nm, to identify H. pylori enzymes responsible for its activation and mode of action. Three enzymes that reduce NTZ were identified: two related NADPH nitroreductases, which also mediate susceptibility to metronidazole (MTZ) (RdxA and FrxA), and pyruvate oxidoreductase (POR). Recombinant His-tagged RdxA, FrxA, and POR, overexpressed in nitroreductase-deficient Escherichia coli, each rapidly reduced NTZ, whereas only FrxA and to a lesser extent POR reduced nitrofuran substrates (furazolidone, nitrofurantoin, and nitrofurazone). POR exhibited no MTZ reductase activity either in extracts of H. pylori or following overexpression in E. coli; RdxA exhibited no nitrofuran reductase activity, and FrxA exhibited no MTZ reductase activity. Analysis of mutation to rifampin resistance (Rif(r)) indicated that NTZ was not mutagenic and that nitrofurans were only weakly mutagenic. Alkaline gel DNA electrophoresis indicated that none of these prodrugs caused DNA breakage. In contrast, MTZ caused DNA damage and was strongly mutagenic. We conclude that POR, an essential enzyme, is responsible for most or all of the bactericidal effects of NTZ against H. pylori. While loss-of-function mutations in rdxA and frxA produce a Mtz(r) phenotype, they do not contribute much to the innate susceptibility of H. pylori to NTZ or nitrofurans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12069963      PMCID: PMC127316          DOI: 10.1128/AAC.46.7.2116-2123.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Evaluation of nitrofurantoin combination therapy of metronidazole-sensitive and -resistant Helicobacter pylori infections in mice.

Authors:  P J Jenks; R L Ferrero; J Tankovic; J M Thiberge; A Labigne
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Systematic identification of selective essential genes in Helicobacter pylori by genome prioritization and allelic replacement mutagenesis.

Authors:  A F Chalker; H W Minehart; N J Hughes; K K Koretke; M A Lonetto; K K Brinkman; P V Warren; A Lupas; M J Stanhope; J R Brown; P S Hoffman
Journal:  J Bacteriol       Date:  2001-02       Impact factor: 3.490

3.  Nitazoxanide, a nitrothiazolide antiparasitic drug, is an anti-Helicobacter pylori agent with anti-vacuolating toxin activity.

Authors:  Y Yamamoto; A Hakki; H Friedman; S Okubo; T Shimamura; P S Hoffman; J Rossignol
Journal:  Chemotherapy       Date:  1999 Jul-Aug       Impact factor: 2.544

4.  In vitro and in vivo activities of nitazoxanide against Clostridium difficile.

Authors:  C S McVay; R D Rolfe
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

5.  Quantitative structure-activity relationships in two-electron reduction of nitroaromatic compounds by Enterobacter cloacae NAD(P)H:nitroreductase.

Authors:  H Nivinskas; R L Koder; Z Anusevicius; J Sarlauskas; A F Miller; N Cenas
Journal:  Arch Biochem Biophys       Date:  2001-01-01       Impact factor: 4.013

6.  Nitazoxanide: pharmacokinetics and metabolism in man.

Authors:  J Broekhuysen; A Stockis; R L Lins; J De Graeve; J F Rossignol
Journal:  Int J Clin Pharmacol Ther       Date:  2000-08       Impact factor: 1.366

Review 7.  Drug targets and mechanisms of resistance in the anaerobic protozoa.

Authors:  P Upcroft; J A Upcroft
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

8.  Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study.

Authors:  A Pilotto; M Franceschi; M Rassu; G Leandro; L Bozzola; F Furlan; F Di Mario
Journal:  Dig Liver Dis       Date:  2000-11       Impact factor: 4.088

9.  Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H. pylori RdxA(+) (Nitroreductase) gene.

Authors:  G Sisson; J Y Jeong; A Goodwin; L Bryden; N Rossler; S Lim-Morrison; A Raudonikiene; D E Berg; P S Hoffman
Journal:  J Bacteriol       Date:  2000-09       Impact factor: 3.490

10.  Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance.

Authors:  D H Kwon; M Lee; J J Kim; J G Kim; F A El-Zaatari; M S Osato; D Y Graham
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

View more
  67 in total

1.  Susceptibility in vitro of clinically metronidazole-resistant Trichomonas vaginalis to nitazoxanide, toyocamycin, and 2-fluoro-2'-deoxyadenosine.

Authors:  Janelle M Wright; Linda A Dunn; Zygmunt Kazimierczuk; Anita G Burgess; Kenia G Krauer; Peter Upcroft; Jacqueline A Upcroft
Journal:  Parasitol Res       Date:  2010-06-09       Impact factor: 2.289

2.  Synthesis and antimicrobial evaluation of nitazoxanide-based analogues: identification of selective and broad spectrum activity.

Authors:  T Eric Ballard; Xia Wang; Igor Olekhnovich; Taylor Koerner; Craig Seymour; Joseph Salamoun; Michelle Warthan; Paul S Hoffman; Timothy L Macdonald
Journal:  ChemMedChem       Date:  2010-12-29       Impact factor: 3.466

3.  Mutations in Helicobacter pylori porD and oorD genes may contribute to furazolidone resistance.

Authors:  Zhaoliang Su; Huaxi Xu; Chiyu Zhang; Shihe Shao; Liangju Li; Hua Wang; Huifang Wang; Gufeng Qiu
Journal:  Croat Med J       Date:  2006-06       Impact factor: 1.351

4.  In vitro effects of thiazolides on Giardia lamblia WB clone C6 cultured axenically and in coculture with Caco2 cells.

Authors:  Joachim Müller; Géraldine Rühle; Norbert Müller; Jean-François Rossignol; Andrew Hemphill
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 5.  New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development.

Authors:  Masayuki Igarashi; Yoshimasa Ishizaki; Yoshiaki Takahashi
Journal:  J Antibiot (Tokyo)       Date:  2017-11-01       Impact factor: 2.649

6.  Second-line and third-line trial for helicobacter pylori infection in patients with duodenal ulcers: A prospective, crossover, controlled study.

Authors:  György M Buzás; Hajnalka Györffy; Ilona Széles; Anna Szentmihályi
Journal:  Curr Ther Res Clin Exp       Date:  2004-01

7.  Nitazoxanide inhibits biofilm production and hemagglutination by enteroaggregative Escherichia coli strains by blocking assembly of AafA fimbriae.

Authors:  Eliah R Shamir; Michelle Warthan; Sareena P Brown; James P Nataro; Richard L Guerrant; Paul S Hoffman
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

Review 8.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

Review 9.  A review and meta-analysis of the impact of intestinal worms on child growth and nutrition.

Authors:  Andrew Hall; Gillian Hewitt; Veronica Tuffrey; Nilanthi de Silva
Journal:  Matern Child Nutr       Date:  2008-04       Impact factor: 3.092

10.  Response to metronidazole and oxidative stress is mediated through homeostatic regulator HsrA (HP1043) in Helicobacter pylori.

Authors:  Igor N Olekhnovich; Serhiy Vitko; Meaghan Valliere; Paul S Hoffman
Journal:  J Bacteriol       Date:  2013-12-02       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.